(NBC News) A new study finds many women with early-stage cancer may be able to skip chemotherapy.
A gene test called “Oncotype DX” has been guiding doctors for years on whether women need chemo if early stage, estrogen-fueled breast cancer that hasn’t spread.
A low test score means patients can forgo the treatment, as well as its toxic side effects, while a high score means women would greatly benefit.
For years doctors were unsure how to treat women who fell in the middle range of the scoring system. Now research on more than 10,000 patients finds those mid-range women can safely be spared chemotherapy without affecting survival rates.
Read more: https://nbcnews.to/2LnfeeF